Evidence map›Paper›PMID 26785742›Full record

Trial reportArthritis research & therapy2016

B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure.

Sebastian Costa, Sacha Schutz, Divi Cornec, Arnaud Uguen, Isabelle Quintin-Roué, Agnès Lesourd, Jean-Marie Berthelot, Eric Hachulla, Pierre-Yves Hatron, Vincent Goeb and 5 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Arthritis research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00740948 (Tolerance and Efficacy of Rituximab in Sjogren's Disease), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00740948 phase2 / phase3completednot on this map

Tolerance and Efficacy of Rituximab in Sjogren's Disease

TypeinterventionalSponsorUniversity Hospital, BrestRan2008 to 2013Enrolled122ConditionsSjogren's DiseaseArmsRituximab (mabthera) Injection, Placebo: NaCl 0.9% or Glucose 5%
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  2. Article
  3. Article
  4. Cytotoxic CD8Scientific reports · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Sebastian CostaPathology Department, Brest University Hospital, Brest, France. sebastian.costa@chu-brest.fr.
Sacha SchutzBiology Department, Brest University Hospital, Brest, France. sacha@labsquare.org.
Divi CornecRheumatology Department, Brest University Hospital, Brest, France. divi.cornec@chu-brest.fr.
Arnaud UguenPathology Department, Brest University Hospital, Brest, France. arnaud.uguen@chu-brest.fr.
Isabelle Quintin-RouéPathology Department, Brest University Hospital, Brest, France. isabelle.quintin-roue@chu-brest.fr.
Agnès LesourdPathology Department, Vannes General Hospital, Vannes, France. agnes.lesourd@ch-bretagne-atlantique.fr.
Jean-Marie BerthelotRheumatology Department, Hôtel Dieu University Hospital, Nantes, France. jeanmarie.berthelot@chu-nantes.fr.
Eric HachullaDepartment of Internal Medicine, Nord-de-France University, Claude-Huriez Hospital, Lille, France. eric.hachulla@chru-lille.fr.
Pierre-Yves HatronDepartment of Internal Medicine, Nord-de-France University, Claude-Huriez Hospital, Lille, France. pierre-yves.hatron@chru-lille.fr.
Vincent GoebRheumatology Department, Amiens University Hospital, Amiens, France. Goeb.vincent@chu-amiens.fr.
Olivier VittecoqRheumatology Department, Rouen University Hospital, Rouen, France. olivier.vittecoq@chu-rouen.fr.
Jacques Olivier PersEA 2216-ESPRI 29, Brest University, Brest, France. pers@univ-brest.fr.
Pascale MarcorellesPathology Department and EA 4685, Brest University Hospital, Brest, France. pascale.marcorelles@chu-brest.fr.
Alain SarauxRheumatology Department and EA 2216-ESPRI 29, Brest University Hospital, Brest, France. alain.saraux@chu-brest.fr.
Valérie Devauchelle-PensecRheumatology Department and EA 2216-ESPRI 29, Brest University Hospital, Brest, France. valerie.devauchelle-pensec@chu-brest.fr.
Centre Hospitalier Régional Universitaire de Brest · FRUniversité de Rouen Normandie · FRCentre Oscar Lambret · FRÉcole nationale supérieure de techniques avancées Bretagne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvaluating lymphocytic infiltration of minor salivary gland biopsy in primary Sjögren's syndrome is challenging. We developed and evaluated a digital method for quantifying B and T lymphocytes in whole minor salivary gland biopsy slides.

methodsMinor salivary gland biopsies were immunostained with anti-CD20/anti-CD3 antibodies using red/brown chromogens. Slides were digitised and spliced into mosaics of smaller JPEG format images in which red and brown pixels were counted. ImageJ Cell counter was used for validation. Agreement between the digital and manual methods was evaluated using Bland-Altman plots and the interclass correlation coefficient. External validation relied on the Chisholm-Mason, Tarpley, and focus-score methods.

resultsOf 62 minor salivary gland biopsy slides, 61.3 % had a Chisholm-Mason grade ≥ III or a focus score ≥1. The number of pixels correlated well with manual cell counts (r = 0.95 for red pixels vs. B cell count and r = 0.91 for brown pixels vs. T cell count). Interclass correlation coefficients between digital and manual counts were excellent (0.92 for B/T cells). B-cell proportion showed a significant positive correlation with the focus score (Spearman's coefficient 0.463, p < 0.0001). Median B-cell proportion was lower in minor salivary gland biopsies with Chisholm grades I-II (2.5 % (0.2-13.9)) than III-IV (30.0 % (15.5-45.2)) and increased with Tarpley's class (1, 2.2 % (0.2-6.6); 2, 27.2 % (13.0-38.9); and 3-4, 48.5 % (29.4-56.4); p < 0.001 for all comparisons). Minor salivary gland biopsy B-cell proportion was also significantly correlated with several markers of clinical and biological activity of the disease, especially with markers of systemic B-cell hyperactivation.

conclusionThe digital procedure proved accurate compared to the reference standard, producing reliable results for whole tissue sections.

trial registrationClinicalTrials.gov [ NCT00740948 ]. Registered 22 August 2008.

Indexed as

AdultAgedB-LymphocytesFemaleHumansLymphocyte CountMaleMiddle AgedSalivary Glands, MinorSjogren's SyndromeT-Lymphocytes

Identifiers

PMID26785742
PMCPMC4719698
OpenAlexW2278262965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.